XNASPTGX
Market cap2.24bUSD
Jan 08, Last price
37.62USD
1D
-2.16%
1Q
-13.70%
Jan 2017
71.08%
IPO
225.15%
Name
Protagonist Therapeutics Inc
Chart & Performance
P/E
—
P/S
37.37
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
20.48%
Rev. gr., 5y
14.17%
Revenues
60m
+125.73%
Net income
-79m
L-36.02%
CFO
-70m
L-35.05%
Earnings
Feb 25, 2025
Profile
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 60,000 125.73% | 26,581 -2.84% | |||||||
Cost of revenue | 153,652 | 158,986 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (93,652) | (132,405) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (3,980) | ||||||||
Tax Rate | |||||||||
NOPAT | (93,652) | (128,425) | |||||||
Net income | (78,955) -36.02% | (123,413) 0.64% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 132,100 | 18,838 | |||||||
BB yield | -10.15% | -3.52% | |||||||
| Debt | |||||||||
Debt current | 2,282 | 2,515 | |||||||
Long-term debt | 1,141 | 4,797 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | (221) | 783,542 | |||||||
Net debt | (338,194) | (230,268) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (70,236) | (108,137) | |||||||
CAPEX | (609) | (795) | |||||||
Cash from investing activities | (39,258) | 91,468 | |||||||
Cash from financing activities | 170,477 | 18,838 | |||||||
FCF | (91,175) | (126,317) | |||||||
| Balance | |||||||||
Cash | 341,617 | 237,355 | |||||||
Long term investments | 225 | ||||||||
Excess cash | 338,617 | 236,251 | |||||||
Stockholders' equity | (615,814) | (537,114) | |||||||
Invested Capital | 954,552 | 756,378 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 56,764 | 49,042 | |||||||
Price | 22.93 110.17% | 10.91 -68.10% | |||||||
Market cap | 1,301,588 143.26% | 535,051 -66.23% | |||||||
EV | 963,394 | 304,783 | |||||||
EBITDA | (90,340) | (129,036) | |||||||
EV/EBITDA | |||||||||
Interest | 3,369 | ||||||||
Interest/NOPBT | |||||||||